Loading
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
NASDAQHealthcareBiotechnology
Latest quote
$1.99
+$0.01 · +0.51%
Latest quote
$1.99
+$0.01 · +0.51%
After-hours
$1.98
−$0.01 · -0.50%
Oct 8, 4:10 PM ET
Regular session · ET · Market data may be delayed.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
Day range
Current $1.99
52-week range
Current $1.99
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
48
Mixed
Risk
64
High Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
Day range
Current $1.99
52-week range
Current $1.99
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 451K USD | — | — | — |
| Cost of goods sold | — | 448K USD | — | 1K USD | 1K USD |
| Gross profit | — | 3K USD | — | −1K USD | −1K USD |
| Research and development | 28K USD | 98K USD | 31K USD | 30K USD | 30K USD |
| Selling, general, and administrative | 1.13M USD | 2.05M USD | 734K USD | 850K USD | 1M USD |
| Operating expenses | 1.69M USD | 2.18M USD | 765K USD | 880K USD | 1.03M USD |
| Interest income | 60K USD | 34K USD | 41K USD | 36K USD | 8K USD |
| Interest expense | 7K USD | 86K USD | 4K USD | 11K USD | 21K USD |
| Depreciation and amortization | — | 199K USD | 1K USD | 1K USD | 1K USD |
| Operating income | −1.69M USD | −2.17M USD | −765K USD | −880K USD | −1.03M USD |
| Net income | −6.97M USD | −1.03M USD | −1.78K USD | −1.35M USD | 435K USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 25, 2026 | 1:4 | — | — |
Stock split | Dec 24, 2025 | 1:4 | — | — |
Stock split | Feb 10, 2017 | 1:5 | — | — |
Stock split | Oct 4, 2012 | 1:10 | — | — |
Effective Mar 25, 2026
1:4
Effective Dec 24, 2025
1:4
Effective Feb 10, 2017
1:5
Effective Oct 4, 2012
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
